Biosignals modulated by tumor-associated carbohydrate antigens: Novel targets for cancer therapy

Annals of the New York Academy of Sciences

Volumn 1086, Issue , 2006, Pages 185-198

  Furukawa, Koichi ^a   Hamamura, Kazunori ^a   Aixinjueluo, Wei ^a   Furukawa, Keiko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

GD2; GD3; Glycolipids; Invasion; Lung cancer; Melanoma; Proliferation

Indexed keywords

ADAPTOR PROTEIN; ANTINEOPLASTIC AGENT; CARBOHYDRATE ANTIGEN; CRK ASSOCIATED SUBSTRATE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FOCAL ADHESION KINASE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD3; GLYCOSPHINGOLIPID; GLYCOSYLTRANSFERASE; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PAXILLIN; PROTEIN ANTIBODY; SMALL INTERFERING RNA; SUGAR; TUMOR ANTIGEN; BCAR1 PROTEIN, HUMAN; GANGLIOSIDE; GANGLIOSIDE, GD2; GANGLIOSIDE, GD3; MONOCLONAL ANTIBODY; TYROSINE;

ANOIKIS; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CELL MEMBRANE; COMPLEX FORMATION; CONFERENCE PAPER; DRUG BINDING; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENETIC MANIPULATION; GENETIC TRANSFECTION; HUMAN; IMMUNOMODULATION; LUNG SMALL CELL CANCER; MELANOMA; MOLECULAR DYNAMICS; NONHODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR CELL LINE; CELL PROLIFERATION; DRUG EFFECT; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REVIEW; SMALL CELL CARCINOMA;

ANOIKIS; ANTIBODIES, MONOCLONAL; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CRK-ASSOCIATED SUBSTRATE PROTEIN; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GANGLIOSIDES; GLYCOSPHINGOLIPIDS; HUMANS; LUNG NEOPLASMS; MELANOMA; NEOPLASM INVASIVENESS; PAXILLIN; PHOSPHORYLATION; TYROSINE;

EID: 34447511417     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1377.017     Document Type: Conference Paper

References (39)

1. SCHENGRUND, C.L. 1990. The role(s) of gangliosides in neural differentiation and repair: a perspective. Brain Res. Bull. 24: 131-141.
2. CAHAN, L.D., R.F. IRIE, R. SINGH, et al. 1982. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc. Natl. Acad. Sci. USA 79: 7629-7633.
3. FURUKAWA, K. & K.O. LLOYD. 1990. Gangliosides in melanoma. In Human Melanoma: From Basic Research to Clinical Application, S. Ferrone, Ed.: 15-30. Springer. Heidelberg.
4. DIPPOLD, W.G., K.O. LLOYD, L.T. LI, et al. 1980. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc. Natl. Acad. Sci. USA 77: 6114-6118.
5. PUKEL, C.S., K.O. LLOYD, L.R. TRAVASSOS, et al. 1982. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J. Exp. Med. 155: 1133-1147.
6. CHEUNG, N.K., U.M. SAARINEN, J.E. NEELY, et al. 1985. Coccia. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 45: 2642-2649.
7. MERRITT, W.D., J.T. CASPER, S.J. LAUER, et al. 1987. Expression of GD3 ganglioside in childhood T-cell lymphoblastic malignancies. Cancer Res. 47: 1724-1730.
8. SIDDIQUI, B., J. BUEHLER, M.W. DEGREGORIO, et al. 1984. Differential expression of ganglioside GD3 by human leukocytes and leukemia cells. Cancer Res. 44: 5262-5265.
9. OKADA, M., K. FURUKAWA, S. YAMASHIRO, et al.1996. High expression of ganglioside alpha-2,8-sialyltransferase (GD3 synthase) gene in adult T-cell leukemia cells unrelated to the gene expression of human T-lymphotropic virus type I. Cancer Res. 56: 2844-2848.
10. tax. Proc. Natl. Acad. Sci. USA 90: 1972-1976.
11. LLOYD, K.O. & K. FURUKAWA. 1998. Biosynthesis and functions of gangliosides: recent advances. Glycoconj. J. 15: 627-636.
12. NAGATA, Y., S. YAMASHIRO, J. YODOI, et al. 1992. Expression cloning of beta 1,4 N-acetylgalactosaminyltransferase cDNAs that determine the expression of GM2 and GD2 gangliosides. J. Biol. Chem. 267: 12082-12089.
13. HARAGUCHI, M., S. YAMASHIRO, A. YAMAMOTO, et al. 1994. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc. Natl. Acad. Sci. USA 91: 10455-10459.
14. MIYAZAKI, H., S. FUKUMOTO, M. OKADA, et al. 1997. Expression cloning of rat cDNA encoding UDP-galactose:GD2 beta1,3-galactosyltransferase that determines the expression of GD1b/GM1/GA1. J. Biol. Chem. 272: 24794-24799.
15. FUKUMOTO, S., H. MIYAZAKI, G. GOTO, et al. 1999. Expression cloning of mouse cDNA of CMP-NeuAc: lactosylceramide alpha2,3-sialyltransferase, an enzyme that initiates the synthesis of gangliosides. J. Biol. Chem. 274: 9271-9276.
16. KOJIMA, Y., S. FUKUMOTO, K. FURUKAWA, et al. 2000. Molecular cloning of globotriaosylceramide/CD77 synthase, a glycosyltransferase that initiates the synthesis of globo series glycosphingolipids. J. Biol. Chem. 275: 15152-15156.
17. OKAJIMA, T., Y. NAKAMURA, M. UCHIKAWA, et al. 2000. Expression cloning of human globoside synthase cDNAs. Identification of beta 3Gal-T3 as UDP-N-acetylgalactosamine: globotriaosylceramide beta 1,3-N-acetylgalactosaminyltransferase. J. Biol. Chem. 275: 40498-40503.
18. PORTOUKALIAN, J., G. ZWINGELSTEIN & J.F. DORE. 1979. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur. J. Biochem. 94: 19-23.
19. CARUBIA, J.M., R.K. YU, L.J. MACALA, et al. 1984. Gangliosides of normal and neoplastic human melanocytes. Biochem. Biophys. Res. Commun. 120: 500-504.
20. YAMASHIRO, S., M. OKADA, M. HARAGUCHI, et al. 1995. Expression of alpha 2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes. Glycoconj. J. 12: 894-900.
21. URMACHER, C., C. CORDON-CARDO & A.N. HOUGHTON. 1989. Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. Am. J. Dermatopathol. 11: 577-581.
22. YU, R.K., L.J. MACALA, T. TAKI, et al. 1988. Developmental changes in ganglioside composition and synthesis in embryonic rat brain. J. Neurochem. 50: 1825-1829.
23. NAKANO, J., B.K. RAJ, C. ASAGAMI, et al. 1996. Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics. J. Invest. Dermatol. 107: 543-548.
24. HAMAMURA, K., K. FURUKAWA, T. HAYASHI, et al. 2005. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc. Natl. Acad. Sci. USA 102: 11041-11046.
25. OGATA, S., Y. FURUHASHI & M. EISINGER. 1987. Growth stimulation of human melanocytes: identification and characterization of melanoma-derived melanocyte growth factor (M-McGF). Biochem. Biophys. Res. Commun. 146: 1204-1211.
26. MARQUARDT, H., M.W. HUNKAPILLER, L.E. HOOD, et al. 1983. Transforming growth factors produced by retrovirus- transformed rodent fibroblasts and human melanoma cells: amino acid sequence homology with epidermal growth factor. Proc. Natl. Acad. Sci. USA 80: 4684-4688.
27. WESTERMARK, B., A. JOHNSSON, Y. PAULSSON, et al. 1986. Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc. Natl. Acad. Sci. USA 83: 7197-7200.
28. CHERESH, D.A., J. ROSENBERG, K. MUJOO, et al. 1986. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res. 46: 5112-5118.
29. GRANT, S.C., L. KOSTAKOGLU, M.G. KRIS, et al. 1996. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur. J. Nucl. Med. 23: 145-149.
30. YOSHIDA, S., S. FUKUMOTO, H. KAWAGUCHI, et al. 2001. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 61: 4244-4252.
31. YOSHIDA, S., H. KAWAGUCHI, S. SATO, et al. 2002. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn. J. Cancer Res. 93: 816-824.
32. AIXINJUELUO, W., K. FURUKAWA, Q. ZHANG, et al. 2005. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J. Biol. Chem. 280: 29828-29836.
33. CRAGG, M.S., R.R. FRENCH & M.J. GLENNIE. 1999. Signaling antibodies in cancer therapy. Curr. Opin. Immunol. 11: 541-547.
34. HOUGHTON, A.N., D. MINTZER, C. CORDON- CARDO, et al. 1985. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA 82: 1242-1246.
35. CHAPMAN, P.B., D. WU, G. RAGUPATHI, et al. 2004. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer Res. 10: 4717-4723.
36. CHEUNG, N.K., H. LAZARUS, F.D. MIRALDI, et al. 1987. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol. 5: 1430-1440.
37. TUO, X.H., S. ITAI, J. NISHIKATA, et al. 1992. Stage-specific expression of cancer-associated type 1 and type 2 chain polylactosamine antigens in the developing pancreas of human embryos. Cancer Res. 52: 5744-5751.
38. TSUCHIDA, A., T. OKAJIMA, K. FURUKAWA, et al. 2003. Synthesis of disialyl Lewis a (Le(a)) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of alpha-series gangliosides. J. Biol. Chem. 278: 22787-22794.
39. MIYAZAKI, K., K. OHMORI, M. IZAWA, et al. 2004. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. Cancer Res. 64: 4498-4505.